Uracz W
Department of Clinical Immunology, Copernicus Medical School, Cracow, Poland.
Immunol Invest. 1988 Aug-Oct;17(6-7):491-506. doi: 10.3109/08820138809030583.
Anti-Iat monoclonal antibodies (mAbs) were found to block the recognition phase of allogeneic mixed lymphocyte reaction (allo-MLR) by reacting with responder T cells but not stimulators. The inhibitory pattern was dependent on the major histocompatibility complex (MHC) of both the responder and stimulator cells. Certain molecules, including IgVH and I-J of stimulator cells were also important. It is suggested that Iat epitopes on alloreactive T cells may serve as a marker of a novel type of a T cell recognition site for Ia. The model of T cell receptor complex with two distinct sites for MHC recognition is proposed.
抗-Iat单克隆抗体(mAbs)被发现可通过与反应性T细胞而非刺激细胞反应来阻断同种异体混合淋巴细胞反应(allo-MLR)的识别阶段。抑制模式取决于反应细胞和刺激细胞的主要组织相容性复合体(MHC)。刺激细胞的某些分子,包括IgVH和I-J也很重要。有人提出,同种异体反应性T细胞上的Iat表位可能作为Ia的新型T细胞识别位点的标志物。提出了具有两个不同MHC识别位点的T细胞受体复合体模型。